Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Tremfya (guselkumab) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorization: 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Tremfya (guselkumab).** Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at:**
http://pithelp.appl.kp.org/MAS/formulary.html

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Provider Name: _____ Specialty: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____Provider Fax #: _____

□ Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #_____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____

Drug 2: Name/Strength/Formulation: _____
Sig: _____

5– Diagnosis/Clinical Criteria

1. Does the member have diagnosis of one of the following? **AND**
   □ Plaque Psoriasis (PsO)
   □ Psoriatic Arthritis (PsA)
   □ Other: _____

2. Was there therapeutic failure on oral methotrexate? **AND**
   □ No □ Yes

3. Was there therapeutic failure to one of the preferred agents? (e.g. Enbrel, Humira) **AND**
   □ No □ Yes

4. If this is being used for plaque psoriasis (PSO):
   a. Is the patient ≥ 18 years old? **AND**
      □ No □ Yes

   b. Does the patient have moderate-to-severe plaque psoriasis for at least 6 months? **AND**
      □ No □ Yes

   c. Is there involvement of at least 10% of body surface area (BSA)? **OR**
      □ No □ Yes

   d. Is the Psoriasis Area and Severity Index (PASI) score 10 or greater? **OR**
      □ No □ Yes

   e. Incapacitation due to plaque location (e.g., head and neck, palms, soles or genitalia)? **AND**
      □ No □ Yes

   f. Has the patient not responded adequately (or is not a candidate) to a 3 month minimum trial of topical agents (e.g., anthralin, coal tar preparations, corticosteroids, emollients, immunosuppressives, keratolytics, retinoic acid derivatives, and/or Vitamin D analogues)? **AND**
      □ No □ Yes

   g. Has the patient not responded adequately (or is not a candidate) to a 3 month minimum trial of at least 1 systemic agent (e.g. Immunosuppressives, retinoic acid derivatives, and/or methotrexate)? **AND**
      □ No □ Yes

   h. Has the patient not responded adequately (or is not a candidate) to a 3 month minimum trial of phototherapy (e.g. Psoralens with UVA light (PUVA) OR UVB with coal tar or dithranol)? **AND**
      □ No □ Yes

   i. Is the patient not receiving guselkumab in combination with another biologic agent for psoriasis or non-biologic immunomodulator (e.g., apremilast, tofacitinib, baricitinib)?
      □ No □ Yes

6 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:	**Date:**

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying,

distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility